With Mother Nature as its lead chemist, Enveda clinches another $150M
Against a backdrop of volatility in the US that has left many biotechs struggling to secure private funding this year, Enveda and its $150-million series D stands out
Read the article on First World Pharma >
Read More from the Global Wellness News ™